New hope for inoperable bile duct cancer: targeted therapies aim to shrink tumors

NCT ID NCT06313203

Recruiting now Disease control Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two treatments for a type of bile duct cancer that cannot be surgically removed. One delivers chemotherapy directly to the liver through a pump, and the other uses tiny radioactive beads injected into the tumor's blood supply. Both are given alongside standard chemotherapy. The goal is to see if these combinations can shrink tumors enough to allow surgery or help patients live longer. About 39 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Floxuridine (via hepatic artery infusion) and Yttrium-90 radioactive particles (via selective internal radiation therapy)
What this could lead to: If successful, this could offer a way to shrink inoperable bile duct tumors enough for surgery, potentially improving survival and giving more patients a chance at a cure.
What could go wrong: This is a small, early-phase trial (39 people) without randomization, so results may not apply broadly. Both treatments have risks like liver damage or infection, and the floxuridine arm requires frequent hospital visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY EFFECT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY EFFECT INTRAHEPATIC CHOLANGIOCARCINOMA

Contacts and locations

Locations

Oslo University Hospital
RECRUITING

Oslo, Oslo, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.